Ampio Rises on Plans for Second Version of Zertane
From Associated Press (July 2, 2012)
NEW YORK -- Ampio Pharmaceuticals Inc. said Monday that it will proceed with developing a version of its experimental drug Zertane that will treat both impotence and premature ejaculation.
Ampio has been studying Zertane only as a treatment for premature ejaculation and now says it wants to study a version of the drug that could treat that condition and impotence. Ampio said Monday that Indian drug maker Syngene will manufacture the combination drug so Ampio and its partner Daewoong Co. can conduct late-stage clinical trials.
Shares of Ampio rose 46 cents, or 9.1 percent, to $5.54 in midday trading. Earlier the stock rose as much as 23 percent.
The Greenwood, Colo., company says it concentrates on winning new marketing approvals for older drugs. The main ingredient of Zertane is tramadol, which has long been used as a pain drug. Ampio does not have any products on the market, but in addition to Zertane it is developing the anti-inflammatory drug Ampion and an eye drug called Optina.
Ampio said it has recently received patents protecting the impotence and premature ejaculation version of Zertane.
Posted: July 2012